Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 8/20 | 0.43 |
| ▸ | CYBB | P04839 | 2/20 | 0.43 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807351 | 0.84 | CYP1A2 (0.56) | HTR1BPLAUHTR1DSLC6A4HRH1 | |
| SCHEMBL24168814 | 0.83 | MCHR1 (0.54) | HTR1BNCF1HTR1DSLC6A4KCNA3 | |
| SCHEMBL30539214 | 0.83 | MCHR1 (0.54) | HTR1BNCF1HTR1DSLC6A4KCNA3 | |
| SCHEMBL1807259 | 0.82 | ALDH1A1 (0.52) | HTR1BPLAU | |
| SCHEMBL229214 | 0.80 | PLAU (0.53) | PLAU | |
| SCHEMBL667918 | 0.80 | HTR1B (0.65) | HTR1BKDM1AHTR1DSLC6A4HRH1 | |
| SCHEMBL30007810 | 0.80 | HTR1B (0.65) | HTR1BKDM1AHTR1DSLC6A4HRH1 | |
| SCHEMBL38658832 | 0.79 | PLAU (0.49) | HTR1BPLAUNCF1CYBBNOX5 | |
| SCHEMBL9466089 | 0.79 | KDM1A (0.49) | HTR1BKDM1AHTR1DSLC6A4HRH1 | |
| SCHEMBL30359494 | 0.79 | NCF1 (0.49) | HTR1BKDM1ANCF1CYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168430-A1 | MULTIKINASE INHIBITOR | REN, RAF1, CHUK | HTR1B 3209/4885KDM1A 989/4885PLAU 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.